Mohammad Hassan Kheirandish
Overview
Explore the profile of Mohammad Hassan Kheirandish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kheirandish M, Rahmani B, Zarei Jaliani H, Barkhordari F, Mazlomi M, Davami F
Mol Biol Rep
. 2023 May;
50(7):5889-5899.
PMID: 37244887
Background: Conventional methods applied to develop recombinant CHO (rCHO) cell line as a predominant host for mammalian protein expression are limited to random integration approaches, which can prolong the process...
2.
Rahmani B, Kheirandish M, Ghanbari S, Raz A, Shamsi F, Davami F
Sci Rep
. 2023 Feb;
13(1):3116.
PMID: 36813818
CRISPR-mediated integration could be used to develop the recombinant CHO (rCHO) cells by knock-in into the hotspot loci. However, low HDR efficiency besides the complex donor design is the main...
3.
Kheirandish M, Zarei Jaliani H, Rahmani B, Nikukar H
Toxicon
. 2022 Nov;
221:106966.
PMID: 36402121
No abstract available.
4.
Rahmani B, Astani A, Zarei Jaliani H, Kheirandish M, Mosaddegh A
Iran J Basic Med Sci
. 2021 Oct;
24(6):851-855.
PMID: 34630963
Objectives: has become a major clinical concern due to the growing prevalence of multi-drug resistant (MDR) strains. Enzybioticts are peptidoglycan hydrolases that are recently introduced as an alternative agent to...
5.
Kheirandish M, Zarei Jaliani H, Rahmani B, Nikukar H
Toxicon
. 2019 Apr;
164:82-86.
PMID: 30991063
Conventional drug delivery systems have many limitations including cytotoxicity and affecting non-specific cells. Cell-targeting peptides (CTPs) as a potential class of targeting moiety have some advantages over previous targeting moieties...
6.
Azadpour M, Karimian M, Kheirandish M, Asadi-Saghandi A, Imani M, Astani A, et al.
Iran J Basic Med Sci
. 2018 Dec;
21(9):878-883.
PMID: 30524686
Objectives: Current therapeutic strategies for cancer are associated with side effects and lack of specificity in treatments. Biological therapies including monoclonal antibodies and immune effectors have been the subject of...
7.
Imani M, Zarei Jaliani H, Kheirandish M, Azadpour M
Iran J Basic Med Sci
. 2017 Oct;
20(4):380-385.
PMID: 29026495
Objectives: A newly-introduced protein toxin from a sea anemone, namely fragaceatoxin C is a protein with molecular weight of 20 kDa and pore-forming capability against cell membranes has recently grasped...